eBook: The current bioanalytical landscape for biosimilars
Biosimilars are biological medicines that are highly similar to another prior approved product that has been shown to have no clinically relevant differences from the original product. Here we explore how high-quality analytical methods and comparability assessments are key to gaining approval for new biosimilar products, and how this is particularly important in the period up to 2030, during which we’ll see several ‘blockbuster’ biologics coming off patent.
CONTENTS INCLUDE:
- INTERVIEW: Biosimilars in healthcare
- EXPERT OPINION: The global landscape on interchangeability of biosimilars
- PERSPECTIVE: Strategies to improve comparability assessments across bioanalytical data for biosimilar studies
- INTERVIEW: Innovation in LC–MS and analytical instrumentation
- EXPERT OPINION: Biosimilars: A futuristic fast-to-market advice to developers
In association with:
